Eupraxia Pharmaceuticals Inc
TSX:EPRX

Watchlist Manager
Eupraxia Pharmaceuticals Inc Logo
Eupraxia Pharmaceuticals Inc
TSX:EPRX
Watchlist
Price: 7.645 CAD 3.45% Market Closed
Market Cap: 274.1m CAD

Eupraxia Pharmaceuticals Inc
Investor Relations

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.

Show more
Loading
EPRX
S&P TSX Composite Index (Canada)

Earnings Calls

No Earnings Calls Available

Management

Dr. James A. Helliwell FRCPC, M.D.
CEO & Director
No Bio Available
Mr. Bruce G. Cousins C.A., CPA
President & CFO
No Bio Available
Dr. Amanda Malone Ph.D.
Chief Scientific Officer & COO
No Bio Available
Mr. Paul Anthony Brennan B.Sc., M.Sc.
Chief Business Officer
No Bio Available
Dr. Mark M. Kowalski M.D., Ph.D.
Chief Medical Officer
No Bio Available
Dr. Rahul Sarugaser M.B.A., Ph.D.
Executive Vice President of Corporate Development
No Bio Available

Contacts

Address
BRITISH COLUMBIA
Victoria
2067 Cadboro Bay Road, #201
Contacts
+12505903968.0
eupraxiapharma.com